Myelodysplastic syndromes: disease overview and therapy options.
The increase in new cases of myelodysplastic syndromes is likely attributable to both an aging population and a greater number of cancer survivors who have received chemotherapy. A detailed diagnostic history is critical in order to place a patient in the proper treatment category.
Coutré
Steven
S
Stanford University School of Medicine, Calif, USA.
D002908:Chronic Disease; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D017707:Erythrocyte Transfusion; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D010346:Patient Care Management; D017713:Platelet Transfusion; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012307:Risk Factors
D004791:Enzyme Inhibitors; D006397:Hematinics; D016179:Granulocyte Colony-Stimulating Factor